Clinical trials: Diabetic Neuropathic Pain
Diabetic Neuropathies
Study of DA-9801 to Treat Diabetic Neuropathic Pain
This is a Phase II dose-ranging study to evaluate the effectiveness and safety of DA-9801 in the treatment of pain associated with diabetic neuropathy.
- Trial name
- NCT01813799
- Testing
- DA-9801 300mg, DA-9801 600mg, DA-9801 900mg
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Dong-A ST Co., Ltd.
Diabetic Peripheral Neuropathic Pain
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
The primary purpose of this study is to evaluate the safety and efficacy of medical cannabis aerosol containing 0.25, 0.50, 1.0 milligrams (mg) delta (Δ) 9-tetrahydrocannabinol (THC) inhaled three times a day (TID) compared to…
- Trial name
- NCT06490445
- Testing
- Medical Cannabis
- Where
- 38 sites in Australia, Czechia and 3 more
- Volunteers
- 122 people
- Sponsor
- Syqe Medical
Neuropathic Pain
Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain
The purpose of this study is to evaluate lidocaine as topical treatment for peripheral neuropathic pain (as stand-alone treatment and in combination with systemic treatment)
- Trial name
- NCT00414349
- Testing
- Topical analgesic, oral intake
- Where
- United Kingdom
- Volunteers
- 431 people
- Sponsor
- Grünenthal GmbH
Diabetic Neuropathies
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.
- Trial name
- NCT00322621
- Testing
- Duloxetine
- Where
- 19 sites in Brazil, France and 2 more
- Volunteers
- 216 people
- Sponsor
- Eli Lilly and Company
Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
People suffering from diabetes often have high blood sugar levels. Over time this can affect many organs including the nerves in hands and feet and can cause a nerve pain called diabetic neuropathic pain (DNP).
- Trial name
- NCT04641273
- Testing
- BAY1817080, Pregabalin
- Where
- 42 sites in Czechia, Denmark and 8 more
- Volunteers
- 154 people
- Sponsor
- Bayer
Diabetic Peripheral Neuropathic Pain
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
The purpose of this study is to test the safety and efficacy of study drug LY3526318 for the treatment of diabetic peripheral neuropathic pain (DPNP).
- Trial name
- NCT05177094
- Testing
- LY3526318
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Peripheral Neuropathic Pain
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
- Trial name
- NCT06696443
- Testing
- Suzetrigine
- Where
- 65 sites in United States
- Volunteers
- 455 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Diabetic Peripheral Neuropathic Pain
Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain
This is a multi-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and PK parameter of HL-1186 tablet for diabetic peripheral neuropathic pain.
- Trial name
- NCT07159243
- Testing
- HL-1186
- Volunteers
- 180 people
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Endometriosis Related Pain, Overactive Bladder
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
Researchers are looking for a new way to treat people suffering either from a condition where the bladder is unable to hold urine normally (overactive bladder), or a condition in which tissue similar to the tissue that normally…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04487431
- Testing
- BAY1817080, [14C]BAY1817080
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes
A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain
In this study, subjects with diabetic neuropathic pain (DNP) will be treated for 12 weeks with either placebo, 40 or 80 mg sustained release sodium nitrite (TV1001sr) twice daily.
- Trial name
- NCT02412852
- Testing
- Sodium nitrite
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- TheraVasc Inc.
Diabetic Neuropathy
Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain
Diabetic neuropathy is known to be the most common complication of diabetes, although the estimated prevalence is highly variable, ranging from 1.6 to 90%.
- Trial name
- NCT01863810
- Testing
- KW21052, Lyrica, Lyrica (low dose)
- Where
- South Korea
- Volunteers
- 394 people
- Sponsor
- KunWha Pharmaceutical Co., Ltd.
Pain
Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain
The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain.
- Trial name
- SERENEATI (NCT00799656)
- Testing
- ataciguat (HMR1766)
- Where
- 3 sites in Austria, Czechia and 1 more
- Volunteers
- 62 people
- Sponsor
- Sanofi
Diabetic Peripheral Neuropathic Pain
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of diabetic peripheral neuropathic pain.
- Trial name
- NCT04476108
- Testing
- LY3016859
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathy
A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain
A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.
- Trial name
- NCT01820715
- Testing
- 600㎍ of DA-3030 Injection
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Diabetic Peripheral Neuropathic Pain
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain.
- Trial name
- NCT05620576
- Testing
- LY3857210
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 131 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathies, Pain
The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy
This study is intended to demonstrate that exposure to a high intensity, DC electromagnetic field, as supplied by the investigational device known as the Molecular Magnetic Energizer (MME), will create a clinically meaningful…
- Conditions
- Diabetic Neuropathies, Pain, Neuralgia
- Trial name
- NCT00134524
- Testing
- MME procedure
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Advanced Magnetic Research Institute International
Chronic Pain
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
The primary objective of this study is to evaluate the safety of hydrocodone extended-release tablets when used over a 12-month period in patients with chronic pain, as assessed by adverse events, clinical laboratory results…
- Trial name
- NCT01223365
- Testing
- Hydrocodone ER
- Where
- 54 sites in United States
- Volunteers
- 330 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Diabetic Peripheral Neuropathic Pain (DPNP)
Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIb Clinical Trial of Spray YJ001 for the Treatment of Diabetic Peripheral Neuropathic Pain
The goal of this clinical trial is to learn if YJ001 Spray can treat diabetic patients with Diabetic Peripheral Neuropathic Pain(DPNP).
- Trial name
- NCT07858344
- Testing
- YJ001 spray simulator, YJ001 Spray 240 mg/day, YJ001 Spray 480 mg/day
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Zhejiang Yuejia Pharmaceuticals Co., Ltd.
Diabetic Peripheral Neuropathic Pain
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
- Trial name
- PROGRESS (NCT06203002)
- Testing
- LX9211 (blinded)
- Where
- 108 sites in United States
- Volunteers
- 496 people
- Sponsor
- Lexicon Pharmaceuticals